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Background: Diet has a great impact on the risk of developing features of metabolic syndrome (MetS), type 2
diabetes mellitus (T2DM), and cardiovascular diseases (CVD). We evaluated whether a long-term healthy Nordic diet
(ND) can modify the expression of inflammation and lipid metabolism-related genes in peripheral blood
mononuclear cells (PBMCs) during a 2-h oral glucose tolerance test (OGTT) in individuals with MetS.
Methods: A Nordic multicenter randomized dietary study included subjects (n= 213) with MetS, randomized to a ND
group or a control diet (CD) group applying an isocaloric study protocol. In this sub-study, we included subjects (n = 89)
from three Nordic centers: Kuopio (n = 26), Lund (n = 30), and Oulu (n = 33) with a maximum weight change of ±4 kg,
high-sensitivity C-reactive protein concentration ≤10 mg L−1, and baseline body mass index <39 kg m−2. PBMCs were
isolated, and the mRNA gene expression analysis was measured by quantitative real-time polymerase chain reaction
(qPCR). We analyzed the mRNA expression changes of 44 genes before and after a 2hOGTT at the beginning and the
end of the intervention.
Results: The healthy ND significantly down-regulated the expression of toll-like receptor 4 (TLR4), interleukin 18 (IL18), and
thrombospondin receptor (CD36) mRNA transcripts and significantly up-regulated the expression of peroxisome
proliferator-activated receptor delta (PPARD) mRNA transcript after the 2hOGTT compared to the CD.
Conclusions: A healthy ND is able to modify the gene expression in PBMCs after a 2hOGTT. However, more studies are
needed to clarify the biological and clinical relevance of these findings.
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The metabolic syndrome (MetS) is a cluster of risk fac-
tors increasing the risk of type 2 diabetes mellitus
(T2DM) and cardiovascular diseases (CVD) (Alberti
et al. 2009). Obesity, insulin resistance (IR), and T2DM
are associated with chronic low-grade inflammation
(Bastard et al. 2006; Wellen and Hotamisligil 2005),
which plays a pivotal role in all phases of atherosclerosis
(Libby et al. 2009). Diet has a great impact on the risk of
MetS, T2DM, and CVD (Alberti et al. 2009; Mozaffarian
et al. 2011). Thus, it is crucial to understand the role of
diet and dietary compounds on inflammation in the de-
velopment of these diseases.
A healthy Nordic diet (ND) has been shown to im-
prove lipid profile among hyper-cholesterolemic subjects
(Adamsson et al. 2011). The Systems Biology in Con-
trolled Dietary Interventions and Cohort Studies (SYS-
DIET) study was a multicenter randomized dietary study
in individuals with features of MetS. A healthy ND with
whole-grain products, berries, fruits and vegetables,
rapeseed oil, three fish meals per week, and low-fat dairy
products was compared to an average Nordic diet served
as control diet (CD) (Uusitupa et al. 2013). In the SYS-
DIET study, we showed that an isocaloric healthy ND
improved the lipid profile, low-grade inflammation, and
ambulatory blood pressure among subjects with MetS
(Uusitupa et al. 2013; Brader et al. 2014). No changes in
glucose metabolism were observed since it may be diffi-
cult to improve glucose metabolism in established MetS
without attendant weight loss and very distinct changes
in the diet (Uusitupa et al. 2013).
The peripheral blood mononuclear cells (PBMCs) in-
clude monocytes and lymphocytes, which are cells cen-
tral in inflammation. These cells circulate in the body
and are exposed to nutrients, bioactive food compo-
nents, and metabolic tissues. Alterations in gene expres-
sion levels in these cells may therefore reflect systemic
health (Afman et al. 2014). It has been shown that long-
term dietary intervention studies change the gene ex-
pression of inflammatory genes and genes involved in
lipid metabolism (Myhrstad et al. 2014; van Dijk et al.
2012a; De Mello et al. 2009; Bouwens et al. 2009), sug-
gesting that PMBCs are a good model system identifying
early risk markers (Visvikis-Siest et al. 2007) and are
sensitive to dietary changes.
Stress responses can be more informative than static
homeostasis on nutrition-related health. An acute glu-
cose load of a 2-h oral glucose tolerance test (OGTT) is
such a stress response, monitors the ability of the body
to respond to glucose intake, and is primarily used for
addressing the degree of glucose tolerance and insulin
resistance (van Ommen et al. 2009). Several studies have
shown that an OGTT (Choi et al. 2012; Kempf et al.
2007; Aljada et al. 2006) as well as fat challenge tests(Bouwens et al. 2010; Cruz-Teno et al. 2012; van Dijk
et al. 2012b; Myhrstad et al. 2011) modulate the gene ex-
pression of inflammatory genes in leucocytes and mono-
nuclear cells. PBMCs also reflect the immune
component of the white adipose tissue transcriptome
after OGTT and after oral lipid tolerance test (O’Grada
et al. 2014), and thus, changes in PBMC gene expression
may act as biomarkers of metabolic health not only in
the fasting state but also in the postprandial state
(O’Grada et al. 2014).
Changes in glucose and lipid homeostasis by acute
challenge tests are linked to inflammation. It has been
shown in dietary intervention studies that the quality of
diet affects OGTT response and improves insulin sensi-
tivity and glucose tolerance in individuals with MetS
(Laaksonen et al. 2005; Paniagua et al. 2007). However,
no previous study has examined the long-term effect of
a dietary intervention on the OGTT response using
PBMCs and gene expression analysis.
The main aim of this sub-population of the SYSDIET
study was to investigate if a long-term (18–24 weeks)
healthy ND could modify the expression of inflamma-
tion and lipid metabolism-related genes in PBMCs dur-
ing 2hOGTT in individuals with MetS.
Results
Characteristics of the subjects
At baseline, no differences were observed between the
CD and ND groups related to age, BMI, serum lipids,
glucose, insulin, circulating inflammation markers, lipid-
lowering drugs, antihypertensive drugs, smoking, and
MetS (Table 1). The change in glucose, insulin, triglycer-
ides, and free fatty acids from 0h (fasting) to 2h (after
OGTT) was not significantly different between the CD
and ND groups (P = 0.330, P = 0.845, P = 0.196, and P =
0.681, respectively) (Fig. 1).
Dietary data
The dietary intake of this sub-population is shown in
Table 2. The results are in line with the original analysis
with the whole SYSDIET study population (Uusitupa
et al. 2013). The intake of polyunsaturated fatty acids
was higher and of saturated fatty acids lower in the ND
compared to the CD group. Further, α-linolenic acid,
fiber, β-carotene, vitamin C, vitamin E, folate, potassium,
and magnesium intake were higher in the ND versus the
CD group.
Changes in 2hOGTT gene expression response at baseline
Since it is well known that glucose uptake inhibits pyru-
vate dehydrogenase kinase, isozyme 4 (PDK4), PDK4
mRNA expression in PBMCs was used as a positive con-
trol for the 2hOGTT response. A significant down-
regulation of PDK4 mRNA expression from 0h (fasting)
Table 1 Baseline characteristics of the participants
Number CD Number ND P
Sex (female) 40 25 (63 %) 49 34 (69 %) 0.51
Age (year) 40 55.8 ± 7.8 49 54.4 ± 8.3 0.43
BMI (kg m−2) 40 31.9 ± 2.7 49 31.8 ± 3.1 0.90
Total cholesterol (mM) 40 5.3 ± 1.0 49 5.3 ± 1.0 0.91
LDL cholesterol (mM) 40 3.3 ± 0.9 49 3.2 ± 0.9 0.93
HDL cholesterol (mM) 40 1.3 ± 0.5 49 1.4 ± 0.3 0.51
Fasting triglycerides (mM) 40 1.5 ± 0.5 49 1.5 ± 0.7 0.84
Fasting glucose (mM) 40 5.8 ± 0.6 49 5.8 ± 0.6 0.46
Fasting insulin (pM) 40 59.5 (47.0–82.3) 49 55.0 (41.0–75.5) 0.43
IL1Ra (ng L−1) 40 308.7 (233.4–465.6) 49 203.8 (220.0–502.0) 0.96
IL1β (ng L−1) 39 0.12 (0.12–0.21) 49 0.12 (0.12–0.14) 0.44
IL6 (ng L−1) 40 1.3 (1.1–1.8) 49 1.3 (1.0–1.9) 0.76
IL10 (ng L−1) 39 0.9 (0.8–1.5) 49 0.8 (0.8–1.5) 0.32
sTNFRII (ng L−1) 40 1899.6 ± 415.4 49 1954.5 ± 461.1 0.56
hs-CRP (mg L−1) 40 1.5 (0.9–3.7) 49 1.5 (0.8–2.9) 0.68
HMW adiponectin (μg L−1) 40 3.6 (2.2–6.7) 49 4.0 (2.8–6.5) 0.36
Lipid-lowering drugs 40 13 (33 %) 49 12 (25 %) 0.48
Antihypertensive drugs 40 20 (50 %) 49 31 (63 %) 0.28
Smoking 40 6 (15 %) 49 4 (8 %) 0.34
Metabolic syndrome 40 34 (85 %) 49 42 (86 %) 1.00
Values are expressed as means ± SDs, medians (25th–75th percentiles), or numbers (%)
CD control diet, ND healthy Nordic diet, BMI body mass index, LDL low density lipoprotein, HDL high-density lipoprotein, IL1Ra interleukin-1 receptor antagonist,
IL1β interleukin-1 beta, IL6 interleukin 6, IL10 interleukin 10, sTNFRII tumor necrosis factor receptor 2, hs-CRP high-sensitivity C-reactive protein, HMW adiponectin
human high molecular weight adiponectin
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population (q < 0.0001) (Additional file 1). Transcript
levels of several inflammatory and lipid metabolism-
related genes were regulated after the OGTT (up-
regulation with fold changes between 1.11 and 1.36
and down-regulation with fold changes between 0.72
and 0.93 (q < 0.05)) (Additional file 1).Changes in 2hOGTT gene expression response after
dietary intervention
To study if the healthy ND could change the 2hOGTT
gene expression response in PBMCs, we conducted a
linear multiple regression analysis adjusting for changes
at baseline and differences in the study centers. Among
the 44 genes, the healthy ND significantly down-
regulated the expressions of toll-like receptor 4 (TLR4)
(β = −0.33, q = 0.042), interleukin 18 (IL18) (β = −0.73, q
= 0.042), and CD36 (β = −0.23, q = 0.042) compared to
the CD after the OGTT (Table 3 and Fig. 2a–c). In con-
trast, a healthy ND significantly up-regulated the expres-
sion of peroxisome proliferator-activated receptor delta
(PPARD) (β = 0.21, q = 0.042) compared to the CD after
the OGTT (Table 3 and Fig. 2d).Discussion
In the present study, we found that the healthy ND
modulated the mRNA levels of TLR4, IL18, CD36, and
PPARD differently after the OGTT compared to the CD.
We also showed that several genes related to inflamma-
tion and lipid metabolism were significantly modulated
by an OGTT in PBMCs of subjects with MetS at
baseline.
Immune response and lipid metabolism are closely
linked in metabolic diseases, and alterations in these re-
sponses after a food challenge may play an important
role in the prevention and early detection of diseases
(van Ommen et al. 2009). The healthy ND down-
regulated the expression of TLR4 compared to the CD
group after the OGTT. TLR4 is involved in the pro-
inflammatory response by regulating nuclear factor
kappa B (NFκB) activity (Doyle and O’Neill 2006) and is
a key regulator of immune response. Previously, it has
been reported that an increased TLR4 mRNA expression
in monocytes in individuals with MetS compared to
healthy controls (Hardy et al. 2013) and down-regulation
of the TLR4 mRNA expression by weight loss are associ-
ated with improvement of insulin sensitivity in the indi-
viduals with MetS (De Mello et al. 2008). This would
Fig. 1 Changes in glucose, insulin, triglycerides, and free fatty acids
from 0h to 2hOGTT after intervention. The effect of the healthy ND
compared to the CD on changes in glucose (a), insulin (b),
triglycerides (c), and free fatty acids (d) from 0 h to 2hOGTT after
intervention. The effect of the independent variable study group is
adjusted for changes in glucose, insulin, triglycerides, or free fatty
acids at baseline, study centers, gender, age (log10 transformed),
and body weight at the end of the study. Box plots show the
medians with 25th and 75th percentiles. Whiskers express the
1.5 × interquartile range
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inflammatory and may lead to improvement of insulin
sensitivity via TLR4 down-regulation in the present
study. We were, however, not able to show any improve-
ment in insulin sensitivity or fasting glucose or insulin
concentrations in the main SYSDIET trial (Uusitupa
et al. 2013), suggesting that the number of subjects in
the original study was too low to see an effect. Anyhow,
it may be speculated that the use of PBMC gene expres-
sion analysis could serve as a more sensitive model sys-
tem than measurement of circulating markers of glucose
metabolism.
Interestingly, we observed that the healthy ND re-
duced the IL18 mRNA expression after the OGTT com-
pared to CD. IL18 is a pro-inflammatory cytokine shown
to be a strong predictor of cardiovascular events in eld-
erly men with MetS, and the effect is stronger with ele-
vated fasting glucose (Troseid et al. 2009). The mRNA
expression of IL18 is also increased in obese individuals,
and this increase is correlated with insulin resistance
(Ahmad et al. 2013). Thus, the down-regulation of IL18
mRNA after the OGTT by healthy ND in the present
study may indicate the impact of the ND on disease de-
velopment among the individuals with MetS.
CD36 is a scavenger receptor involved in lipid uptake and
foam cell formation in macrophages (Silverstein 2009).
Intracellular lipids taken up by CD36 activate TLR4, which
generate pro-inflammatory signals by activating NFκB
(Fessler et al. 2009). A blockage of TLR4 and CD36 in hu-
man macrophages reduced secretion of IL1β, IL6, and IL8
and the subsequent foam cell formation (Chavez-Sanchez
et al. 2014). We found a down-regulation of CD36 mRNA
transcript level after the OGTT in the healthy ND group
compared to the CD group. We could speculate that the
beneficial effects of ND may be executed also via reduction
of the foam cell formation and inflammation indicated by
down-regulation of the CD36 mRNA expression in the
postprandial state. In contrast, the PPARD gene transcript
was increased after the OGTT challenge in the ND group
compared to the CD group. PPARD is expressed in several
tissues in the body, including macrophages. The expression
of PPARD genes regulates lipid metabolism and glucose
homeostasis, increases fatty acid oxidation, and decreases
inflammation as well as platelet activation (Monsalve et al.
Table 2 Dietary intake in the CD and healthy ND group at baseline and end of intervention
CD (n = 40) ND (n = 47) Regression coefficient β (95 % CI)
Baseline End Baseline End Unadjusted Adjusted Pa
Energy, kJ 8074 ± 2173 8301 ± 1542 8077 ± 1757 8537 ± 1791 235 (−484 to 954) 297 (−218 to 813) 0.254
Protein, E% 17.2 ± 2.4 17.0 ± 2.3 16.7 ± 2.7 16.8 ± 2.3 −0.1 (−1.1 to 0.9) 0.1 (−0.8 to 1.0) 0.772
Carbohydrate, E% 46.4 ± 2.3 43.2 ± 7.0 45.1 ± 5.8 45.5 ± 5.2 2.3 (0.6 to 4.5) 2.5 (0.5 to 4.4) 0.013
Sucrose, g 40.1 ± 17.3 34.8 ± 15.4 41.2 ± 15.2 37.6 ± 15.6 2.8 (−3.9 to 9.4) 1.8 (−4.0 to 7.6) 0.541
Fat, E% 32.1 ± 6.2 35.7 ± 5.1 32.5 ± 7.3 32.9 ± 5.1 −2.8 (−4.9 to − 0.6) −2.9 (−5.0 to − 0.9) 0.005
SFA, E% 13.0 ± 3.2 15.3 ± 2.9 13.2 ± 3.5 10.8 ± 2.3 −4.5 (−5.6 to − 3.4) −4.8 (−5.8 to − 3.7) <0.001
MUFA, E% 11.5 ± 2.3 12.8 ± 2.0 11.6 ± 2.8 12.7 ± 2.2 −0.1 (−1.0 to 0.8) −0.1 (−0.9 to 0.7) 0.864
PUFA, E% 4.7 ± 1.6 4.5 ± 1.1 4.9 ± 1.4 6.9 ± 1.5 2.5 (1.9 to 3.0) 2.5 (1.9 to 3.0) <0.001
Linoleic acid, g 7.3 ± 2.4 8.2 ± 2.8 8.0 ± 3.0 8.7 ± 3.9 0.5 (−0.9 to 2.0) 0.5 (−0.9 to 1.9) 0.517
α-Linolenic acid, g 1.2 ± 0.6 1.4 ± 0.7 1.2 ± 0.6 2.0 ± 1.4 0.7 (0.2 to 1.2) 0.7 (0.4 to 1.1) <0.001
Fiber, g 21.2 ± 6.5 16.4 ± 4.9 21.7 ± 7.2 36 ± 10.1 19.6 (16.2 to 23.1) 19.5 (16.2 to 22.8) <0.001
Cholesterol, mg 268 ± 127 283 ± 118 254 ± 102 214 ± 74 −69 (−111 to − 28) −58 (−90 to − 25) 0.001
Salt, g 7.2 ± 2.9 7.0 ± 2.0 7.1 ± 2.2 6.5 ± 2.4 −0.4 (−1.4 to 0.5) −0.3 (−1.1 to 0.5) 0.478
β-Carotene, mg 2561 ± 2090 1733 ± 1173 2449 ± 1891 2987 ± 1857 1254 (578 to 1930) 1213 (543 to 1884) 0.001
Vitamin C, mg 120 ± 100 66 ± 32 112 ± 59 138 ± 50 72 (54 to 90) 72 (54 to 91) <0.001
Vitamin E, mg 8.9 ± 3.4 8.2 ± 2.2 9.5 ± 3.4 13.6 ± 3.0 5.3 (4.2 to 6.5) 5.2 (4.1 to 6.2) <0.001
Folate, mg 251 ± 76 226 ± 63 271 ± 83 343 ± 172 117 (60 to 174) 104 (51 to 158) <0.001
Sodium, mg 2855 ± 1151 2722 ± 78 2813 ± 878 2654 ± 980 −68 (−451 to 314) −27 (−337 to 284) 0.865
Potassium, mg 3711 ± 1175 3276 ± 933 3626 ± 975 4017 ± 910 742 (348 to 1135) 767 (482 to 1053) <0.001
Magnesium, mg 359 ± 111 309 ± 82 370 ± 101 421 ± 101 112 (73 to 152) 106 (79 to 132) <0.001
Calcium, mg 1006 ± 411 951 ± 383 967 ± 370 997 ± 310 46 (−102 to 193) 60 (−43 to 163) 0.250
Alcohol, E% 2.1 ± 2.8 3.0 ± 3.3 3.0 ± 4.1 1.8 ± 2.9 −1.2 (−2.5 to 0.1) −1.2 (−2.3 to − 0.1) 0.036
Values are means ± SDs
CD control diet, ND healthy Nordic diet, E % percentage of energy, SFA saturated fatty acids, MUFA monounsaturated fatty acids, PUFA polyunsaturated fatty acids
aWith linear multivariable regression analysis, the effect of the independent variable “study group” adjusted for dietary data at baseline, study center, gender,
log10-transformed age, and body weight at the end of the intervention was assessed. The regression coefficient expresses the mean difference between the
groups, unadjusted and adjusted. The CD and the ND groups did not differ from each other at baseline (P > 0.05)
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had reduced PBMC gene expression of PPARD compared
with metabolically healthy obese and control subjects
(Telle-Hansen et al. 2013), and PPARD activation improves
multiple metabolic disorders (especially blood lipids) in
obese subjects (Riserus et al. 2008).
In accordance to other studies, the expression of PDK4
was down-regulated (Zhang et al. 2014), and several pro-
inflammatory genes (TNF, TGFB2, CXCR2, CD40LG,
IL1RN, CCR2, IL23R, andMMP9) and lipid metabolism re-
lated genes (CD36, ABCG1 and ABCA1) were up-
regulated, after the OGTT in the whole study population,
confirming the use of PBMC gene expression analysis as a
model system to detect metabolic responses after an OGTT
(Aljada et al. 2006; Aljada et al. 2004; Griffin et al. 2001).
The mRNA level of CPT1A was down-regulated during
2hOGTT. Since CPT1 is involved in oxidation of fatty
acids, and the oxidation is suppressed in the presence of an
adequate glucose supply (Bonnefont et al. 2004), the re-
duced expression of CPT1 during 2hOGTT may beexplained by increased glucose oxidation and decreased
fatty acid oxidation.
The strength of this study is the relatively high number
of subjects, and to the best of our knowledge, the current
dietary intervention study is the first one to use PBMC
gene expression as a tool to examine if diet can modify
the OGTT response. We used a well-characterized
glucose-regulated gene as a positive control to ensure that
changes in mRNA level could be measured 2h after
OGTT. The limitation of the study is that we cannot dif-
ferentiate any specific food components responsible for
the effect on the change in 2hOGTT response since we
did not focus the intervention on single nutrients but on
the whole diet. Our primary aim was however to study the
effects of the whole diet, since this approach is closer to
real-life situations.
Conclusions
We show that the long-term intake of a healthy ND
down-regulates genes involved in inflammation and lipid
Table 3 Effect of the healthy ND compared to the CD on gene expression changes after 2hOGTT
Number Group effect (regression coefficient β) 95 % CI for β q values
Inflammatory genes
CCL2
Unadjusted 78 0.12 −0.19–0.43 0.64
Adjusted 78 0.12 −0.20–0.42 0.69
CCL5
Unadjusted 85 −0.002 −0.14–0.14 0.98
Adjusted 85 −0.002 −0.14–0.14 0.98
CCR2
Unadjusted 76 −0.06 −0.27–0.15 0.72
Adjusted 76 −0.07 −0.28–0.14 0.69
CCR4
Unadjusted 77 −0.07 −0.23–0.10 0.64
Adjusted 77 −0.06 −0.22–0.11 0.69
CD40
Unadjusted 87 −0.14 −0.37–0.10 0.46
Adjusted 87 −0.03 −0.25–0.19 0.88
CD40LG
Unadjusted 87 −0.09 −0.22–0.04 0.42
Adjusted 87 −0.08 −0.21–0.06 0.47
CXCR2
Unadjusted 86 −0.27 −0.47–(−0.07) 0.05
Adjusted 86 −0.25 −0.45–(−0.05) 0.09
ICAM1
Unadjusted 84 −0.02 −0.22–0.19 0.89
Adjusted 84 0.02 −0.19–0.22 0.93
IFNG
Unadjusted 86 −0.29 −0.53–(−0.05) 0.09
Adjusted 86 −0.27 −0.51–(−0.02) 0.13
IKBKB
Unadjusted 83 −0.24 −0.41–(−0.06) 0.05
Adjusted 83 −0.24 −0.42–(−0.06) 0.08
IL18
Unadjusted 72 −0.60 −1.01–(−0.18) 0.05
Adjusted 72 −0.73 −1.20–(−0.26) 0.042
IL1B
Unadjusted 85 −0.17 −0.43–0.10 0.42
Adjusted 85 −0.16 −0.41–0.09 0.45
IL1RN
Unadjusted 87 −0.10 −0.26–0.06 0.42
Adjusted 87 −0.10 −0.26–0.06 0.47
IL23A
Unadjusted 87 0.15 0.00–0.31 0.17
Adjusted 87 0.14 −0.01–0.30 0.20
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IL23R
Unadjusted 88 −0.06 −0.36–0.24 0.78
Adjusted 88 −0.05 −0.34–0.25 0.88
IL6
Unadjusted 86 −0.18 −0.45–0.09 0.42
Adjusted 86 −0.19 −0.46–0.09 0.43
IL8
Unadjusted 83 −0.50 −1.09–0.09 0.30
Adjusted 83 −0.53 −1.12–0.05 0.22
MMP9
Unadjusted 71 −0.09 −0.52–0.34 0.78
Adjusted 71 −0.12 −0.57–0.33 0.74
NFKBIA
Unadjusted 87 0.09 −0.03–0.22 0.37
Adjusted 87 0.10 −0.03–0.22 0.34
OLR1
Unadjusted ND ND ND ND
Adjusted ND ND ND ND
PDGFA
Unadjusted 64 0.21 −0.06–0.48 0.37
Adjusted 64 0.29 0.00–0.57 0.17
PDGFB
Unadjusted 77 0.24 0.03–0.45 0.12
Adjusted 77 0.24 0.03–0.45 0.11
PDK4
Unadjusted 88 −0.14 −0.41–0.13 0.55
Adjusted 88 −0.08 −0.34–0.18 0.70
RELA
Unadjusted 83 −0.06 −0.21–0.10 0.64
Adjusted 83 −0.10 −0.25–0.06 0.45
TGFB2
Unadjusted 75 0.12 −0.15–0.39 0.64
Adjusted 75 0.10 −0.18–0.38 0.69
TLR4
Unadjusted 85 −0.36 −0.54–(−0.18) 0.008
Adjusted 85 −0.33 −0.52–(−0.15) 0.042
TNF
Unadjusted 86 −0.09 −0.23–0.05 0.42
Adjusted 86 −0.09 −0.23–0.05 0.45
TNFRSF1A
Unadjusted 88 −0.24 −0.41–(−0.07) 0.05
Adjusted 88 −0.22 −0.40–(−0.04) 0.09
TNFRSF1B
Unadjusted 88 −0.11 −0.29–0.08 0.46
Adjusted 88 −0.10 −0.28–0.08 0.47
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Lipid metabolism-related genes
ABCA1
Unadjusted 72 −0.12 −0.39–0.16 0.64
Adjusted 72 −0.12 −0.39–0.15 0.64
ABCG1
Unadjusted 81 0.09 −0.14–0.32 0.64
Adjusted 81 0.11 −0.12–0.34 0.60
CD36
Unadjusted 85 −0.24 −0.40–(−0.07) 0.05
Adjusted 85 −0.23 −0.39–(−0.08) 0.042
CPT1A
Unadjusted 78 0.05 −0.17–0.26 0.78
Adjusted 78 0.05 −0.27–0.27 0.80
CPT1B
Unadjusted 82 −0.26 −0.49–(−0.02) 0.12
Adjusted 82 −0.26 −0.49–(−0.03) 0.13
CRAT
Unadjusted 84 0.01 −0.13–0.16 0.89
Adjusted 84 0.02 −0.13–0.17 0.88
HMGCR
Unadjusted 86 0.04 −0.12–0.19 0.78
Adjusted 86 0.04 −0.12–0.20 0.74
LDLR
Unadjusted 73 0.24 0.04–0.45 0.10
Adjusted 73 0.25 0.04–0.46 0.09
LIPE
Unadjusted ND ND ND ND
Adjusted ND ND ND ND
NAMPT
Unadjusted 80 −0.07 −0.25–0.12 0.64
Adjusted 80 −0.06 −0.25–0.12 0.69
PLIN2
Unadjusted 80 0.02 −0.18–0.21 0.89
Adjusted 80 0.004 −0.20–0.20 0.98
PPARA
Unadjusted 87 0.03 −0.15–0.21 0.81
Adjusted 87 0.02 −0.16–0.20 0.88
PPARD
Unadjusted 87 0.22 0.09–0.36 0.021
Adjusted 87 0.21 0.08–0.35 0.042
SREBF1
Unadjusted 81 −0.15 −0.69–0.39 0.74
Adjusted 81 −0.24 −0.77–0.28 0.61
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Table 3 Effect of the healthy ND compared to the CD on gene expression changes after 2hOGTT (Continued)
UCP2
Unadjusted 84 0.16 −0.04–0.36 0.32
Adjusted 84 0.17 −0.02–0.36 0.23
Adjusted models: The effect of the independent variable “study group” is adjusted for fold change at baseline (log2 transformed) and study center. It should be
noted that the regression coefficient expresses the mean difference between the groups, unadjusted and adjusted. A q value <0.05 (FDR < 5 %) were
considered significant
ND not detected
Leder et al. Genes & Nutrition  (2016) 11:3 Page 9 of 13metabolism in individuals at risk for metabolic diseases
and thereby may reduce this unfavorable postprandial
response. The results need to be confirmed by further
human intervention studies, preferably with meal chal-
lenges. In addition, experimental models (e.g., ex vivo
cell models or animal model) should be employed to ex-
tend our biological and clinical understanding of the
data presented here.Fig. 2 Effect of ND compared to CD on gene expression changes after a 2hO
expression (a), IL18 mRNA expression (b), CD36 mRNA expression (c), and PPA
−ΔCt of 0hOGTT) in the healthy ND group (n = 42–49) and in the CD group (n
reference gene TBP and fasting values (0hOGTT). The box plots show the 2−ΔΔ
25th and 75th percentiles. Whiskers express the 1.5 × interquartile range. The
ND compared to the CD on gene expression changes after a 2hOGTT. The ef
at baseline (log2 transformed) and study centers. A q value <0.05 (FDR < 5 %)Methods
Study design and subjects
The study design and participants have been described
in detail elsewhere (Uusitupa et al. 2013). In short, this
study was a randomized controlled multicenter study
performed in six centers within the Nordic countries
[Kuopio and Oulu (Finland), Lund and Uppsala (Sweden),
Aarhus (Denmark), and Reykjavik (Iceland)]. TheGTT. The effect of the healthy ND compared to the CD on TLR4 mRNA
RD mRNA expression (d) presented as fold change (2−ΔCt of 2hOGTT/2
= 32–40) after intervention. Fold changes (2−ΔΔCt) are normalized for the
Ct values at the end of the intervention. Box plots show the medians with
number sign is a q value of 0.042. The q values indicate the effect of the
fect of the independent variable study group is adjusted for fold change
was considered significant
Fig. 3 Flow chart of the participants
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with habitual diet into a healthy ND group or a CD group
for 18–24 weeks. The composition of the diets has been
described in detail elsewhere (Uusitupa et al. 2013). The
main differences between the diets at the nutrient level
were the amount of dietary fiber and salt and the quality
of dietary fat. Both the ND and the CD were isocaloric
based on the evaluation of the habitual diet calculated
from a 4-day food record during the run-in period. The
Nordic Nutrition Recommendations (NNR) formed the
basis of the ND, and the main emphasis was on food items
such as whole-grain products, abundant use of berries,
fruit and vegetables, rapeseed oil, three fish meals per
week, low-fat dairy products, and avoidance of sugar-
sweetened products. The subjects in the CD consumed a
diet in accordance to the mean nutrient intake in the Nor-
dic countries. Key products were provided to the study
participants in both groups. The study participants were
advised to keep body weight and physical activity constant
and not to change their smoking and drinking habits or
drug treatment during the study. All study participants
provided their written informed consent, and local ethics
committees of all the participating centers approved the
study protocol.
Altogether, 309 individuals were originally contacted and
screened at the study clinics, and 213 were randomized as
described earlier (Uusitupa et al. 2013). Ninety-six individ-
uals in the ND group and 70 in the CD group completed
the trial (Uusitupa et al. 2013). The inclusion criteria were
age 30–65 years, BMI 27–38 kg m−2, and two other of the
International Diabetes Federation (IDF) criteria for MetS
(Alberti et al. 2009). Antihypertensive and lipid-lowering
medication, as well as inhaled corticosteroids, were allowed
but without dosage changes during the trial. The main ex-
clusion criteria included any chronic disease and condition,
which could hamper the adherence to the dietary interven-
tion protocol, poor compliance, chronic liver, thyroid and
kidney diseases, alcohol abuse (>40 g per day), diabetes,
fasting triglycerides >3.0 mM, total cholesterol >6.5 mM,
and blood pressure >160/100 mmHg. A few study partici-
pants with triglycerides between 3 and 4 mM and with
BMI between 38 and <40 kg m−2 were, however, included
in the main study population.
In this present sub-study of the SYSDIET trial, we in-
cluded a total of 94 subjects (n = 54 in ND and n = 40 in
CD) out of the 166 subjects who completed the SYS-
DIET study (Fig. 3). We excluded subjects from Aarhus
(n = 31), Uppsala (n = 9), and Reykjavik (n = 15), because
the Aarhus study center did not collect PBMC samples,
and the number of PBMC samples was limited from
Uppsala (n = 9) and Reykjavik (n = 5). So, by excluding
these two centers, we reduced variance. We also ex-
cluded subjects with high-sensitivity C-reactive protein
(hs-CRP) concentration higher than 10 mg L−1 atbaseline or after the intervention (n = 6), baseline BMI
above 39 kg m−2 (n = 3), and body weight change more
than 4 kg during the intervention (n = 8). Since five sub-
jects were excluded from the analysis due to low quan-
tity of RNA (n = 3) or problems with the TaqMan Array
Micro Fluidic Cards (n = 2), we analyzed data from 89
subjects (n = 49 in ND and n = 40 in CD) (Fig. 3).
Clinical and biochemical measurements
Procedures regarding the clinical and biochemical mea-
surements have been described previously (Uusitupa
et al. 2013). In short, subjects were examined in the
morning after overnight fasting. Anthropometric mea-
surements were performed locally according to the
standard operational procedures. Concentrations of
plasma glucose, cholesterol, and triglycerides were ana-
lyzed locally in the centers using routine methodology.
Blood samples to measure cytokines and adipokines
from all the study centers were analyzed in the Univer-
sity of Eastern Finland and Kuopio University Hospital,
Finland. Plasma insulin was analyzed in the Aarhus Uni-
versity Hospital, Denmark, using routine automated
clinical chemistry analyzers.
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A standard 2hOGTT (75 g D-glucose) was performed
after an overnight fast at baseline and at the end of the
intervention. Blood samples for PBMC isolation were
taken at the time points 0 and 120 min.PBMCs, RNA isolation, cDNA synthesis, and qPCR
After blood collection, PBMCs were isolated at base-
line and at the end of the intervention at time points
0 and 120 min by using the BD Vacutainer Cell Prep-
aration tubes according to the manufacturer’s instruc-
tions (Becton, Dickinson San Jose, CA, USA) and
stored as pellets at −80 °C for further analysis. Total
RNA isolation was performed centrally at the Karo-
linska Institute (Stockholm, Sweden). The total RNA
was isolated using the RNeasy Mini Kit according to
the manufacturer’s instructions (Qiagen, Valencia, CA,
USA). RNA quantity and quality measurements were per-
formed using a Nanodrop ND-1000 Spectrophotometer
(Thermo Fisher Scientific, Gothenburg, Sweden) and
Agilent 2100 Bioanalyzer (Agilent Technologies, Santa
Clara, CA, USA), respectively. RNA from all samples was
reverse transcribed by a high-capacity cDNA reverse tran-
scription kit (Applied Biosystems, Foster City, CA, USA).
Quantitative real-time polymerase chain reaction (qPCR)
was performed on an ABI PRISM 7900HT (Applied Bio-
systems) using TaqMan Array Micro Fluidic Cards
(Applied Biosystems). The target genes are shown in the
Additional file 1. Primer sequences are commercially
available (Applied Biosystems) and can be provided upon
request. The selection of target genes was primarily
based on previous long-term and short-term dietary
intervention studies where PBMC gene expression of
inflammatory and lipid metabolism genes was modu-
lated or associated with features of MetS or meta-
bolic risk factors for T2DM and CVD (De Mello
et al. 2009; Bouwens et al. 2009; Jones et al. 2011;
Kaminski et al. 1993) and on results from our own
studies (Myhrstad et al. 2011; Telle-Hansen et al.
2013).
The relative mRNA level for each transcript was
calculated by the ΔΔ cycle threshold (Ct) method
(Livak and Schmittgen 2001). TATA-box binding
protein (TBP) was used as reference gene for
normalization. Briefly, the Ct values of each target
gene were normalized to the Ct values of the TBP
(=ΔCt). The fold change in mRNA gene expression
from TBP was calculated at fasting (0h) and after
(2h) OGTT (2−ΔCt) at baseline and at the end of the
intervention. The fold change in mRNA gene expres-
sion from fasting was calculated as 2−ΔΔCt at baseline
and at the end of the intervention, as 2−ΔCt2hOGTT was
divided by 2−ΔCt0hOGTT.Statistical analysis
For baseline characteristic comparisons, we used inde-
pendent t test to test the difference between means,
Mann-Whitney U test to test the difference between me-
dians and chi-square test to test the difference between
categorical variables. Power calculations (alpha <0.05,
beta >0.8) were carried out on serum cholesterol, fasting
glucose, and insulin (Uusitupa et al. 2013).
Linear multivariable regression analyses were used to
test the independent effect of the study groups on the
change in glucose, insulin, triglycerides, and free fatty
acids from 0h (fasting) to 2h (after OGTT) at the end of
the intervention as well as on the dependent dietary in-
take variables at the end of the intervention. The effect
of the independent variable study group was adjusted for
the corresponding baseline variable, study centers, gen-
der, log10-transformed age, and body weight at the end
of the intervention. Changes in gene expression from 0h
to 2hOGTT within the whole study population were
tested with Wilcoxon signed rank test (2−ΔCt). Data are
given as the median (25–75th percentiles). Linear
multivariable regression analyses were also carried out
to test the independent effect of the study groups on
the dependent variable fold change at the end of the
intervention. The analyses were adjusted for the inde-
pendent variables fold change at baseline and study
center. In the presentation, β denotes the regression
coefficient of the treatment group. Fold changes at
baseline and at the end of the intervention (2−ΔΔCt)
were log2 transformed before the analyses to improve nor-
mality. To account for multiple testing, we applied false
discovery rate (FDR) analysis and q < 0.05 (FDR < 5 %) was
considered significant. Calculations were performed using
IBM SPSS Statistics version 20 (Armonk, NY, USA) and R
version 3.2.0.
Additional file
Additional file 1: mRNA level at fasting (0hOGTT) and after 2hOGTT and
fold change from fasting in the whole study population at baseline. Data
for 0hOGTT and 2hOGTT is given as 2−ΔCt (normalized for TBP). Data for fold
change is given as 2−ΔΔCt (normalized for TBP and 0hOGTT values). All values
are presented as medians with 25th–75th percentiles. (DOCX 21.4 kb)
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